Evofem Biosciences

200 articles about Evofem Biosciences

• Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference

  5/14/2019

  The conference will be held at the InterContinental New York Barclay Hotel in New York, NY.

• Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

  5/7/2019

  Management to Host Conference Call at 11:00 a.m. EDT

• Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019

  4/30/2019

  Evofem Biosciences, Inc., will hold a conference call to discuss financial results and business highlights for the first quarter ended March 31, 2019

• Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora

  4/23/2019

  Evofem Biosciences, Inc. announced the completion of patient enrollment in AMPREVENCE, the Phase 2b clinical trial evaluating its lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator™, for the prevention of chlamydia and gonorrhea in women.

• PDL BioPharma Announces Equity Investment in Evofem Biosciences

  4/11/2019

  Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand female contraceptive

• Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma

  4/11/2019

   Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc.

• Evofem Biosciences to Present at Needham Healthcare Conference

  4/3/2019

  Evofem's management team will host one-on-one meetings with investors during the conference.

• Evofem Biosciences to Present at Upcoming Investor Conferences - March 12, 2019

  3/12/2019

  Evofem Biosciences, Inc.,, a clinical-stage biopharmaceutical company, announced it will present at the following investor conferences on Tuesday March 19, 2019

• Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

  3/1/2019

  Evofem Biosciences, Inc.,, a clinical stage biopharmaceutical company, reported financial results for the three- and twelve- month periods ended December 31, 2018.

• Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019

  2/19/2019

  Evofem Biosciences, Inc., will hold a conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2018

• Evofem Biosciences Provides Corporate Update and Announces Upcoming 2019 Milestones

  1/3/2019

  - Company to Resubmit New Drug Application (NDA) for Amphora as Hormone-free Birth Control in Q2 2019 Based on Positive Top-line Phase 3 Study Results -

• Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control

  12/17/2018

  Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed

• Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018

  11/15/2018

  Evofem Biosciences, Inc. announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference, as follows:

• Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy

  11/8/2018

  Company Remains on Track for AMPOWER Top-line Results in Late 2018

• Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update

  11/7/2018

  Management to Host Conference Call at 11:00 a.m. EST

• Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled

  11/1/2018

  Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced it will host a key opinion leader event in New York City on Thursday, November 15, 2018

• Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018

  10/24/2018

  Conference Call Scheduled for 11:00 a.m. EST

• Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress

  10/9/2018

  Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced details of two oral presentations of data related to their lead product, Amphora®

• Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress

  10/3/2018

  Evofem Biosciences, Inc. will present an update on the methodology and status of two ongoing late stage clinical trials of its lead product candidate, Amphora®.

• Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018

  8/23/2018

  Evofem Biosciences, Inc. announced today that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC